Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3838319 | 1.00 | LMNA (0.38) | LMNAACE2 | |
| SCHEMBL4806963 | 1.00 | LMNA (0.38) | LMNAACE2 | |
| SCHEMBL11324250 | 1.00 | LMNA (0.38) | LMNAACE2 | |
| SCHEMBL5076457 | 1.00 | LMNA (0.38) | LMNAACE2 | |
| SCHEMBL17219813 | 1.00 | LMNA (0.38) | LMNAACE2 | |
| SCHEMBL2461382 | 1.00 | LMNA (0.38) | LMNAACE2 | |
| SCHEMBL5792782 | 1.00 | LMNA (0.38) | LMNAACE2 | |
| SCHEMBL199671 | 1.00 | LMNA (0.38) | LMNAACE2 | |
| SCHEMBL2418061 | 1.00 | LMNA (0.38) | LMNAACE2 | |
| SCHEMBL6764066 | 1.00 | LMNA (0.38) | LMNAACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103228252-A | Compositions comprising a near terminal-ranched compound and methods of making the same | PROCTER & GAMBLE | 2013-07-31 | — | — | CN | claimed |
| EP-1423137-B1 | LIPOPEPTIDE STEREOISOMERS, METHODS FOR PREPARING SAME, AND USEFUL INTERMEDIATES | CUBIST PHARM INC (US) | 2009-04-29 | — | — | EP | claimed |
| US-7482439-B2 | antibiotics; caprazamycin B is subjected to acid-hydrolysis | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 2009-01-27 | — | — | US | claimed |
| EP-1423137-A4 | LIPOPEPTIDE STEREOISOMERS, METHODS FOR PREPARING SAME, AND USEFUL INTERMEDIATES | CUBIST PHARM INC (US) | 2005-11-30 | — | — | EP | claimed |
| EP-1423137-A2 | LIPOPEPTIDE STEREOISOMERS, METHODS FOR PREPARING SAME, AND USEFUL INTERMEDIATES | Cubist Pharmaceuticals, Inc. (US) | 2004-06-02 | — | — | EP | claimed |
| US-20030096948-A1 | Lipopeptide stereoisomers, methods for preparing same, and useful intermediates | ADOLOR CORPORATION | 2003-05-22 | — | — | US | claimed |
| WO-2003017924-A2 | LIPOPEPTIDE STEREOISOMERS, METHODS FOR PREPARING SAME, AND USEFUL INTERMEDIATES | CUBIST PHARMACEUTICALS, INC. (US) | 2003-03-06 | — | — | WO | claimed |
| WO-2024147345-A1 | COATED NEGATIVE ELECTRODE ACTIVE MATERIAL PARTICLES FOR LITHIUM ION BATTERIES, NEGATIVE ELECTRODE FOR LITHIUM ION BATTERIES, LITHIUM ION BATTERY, AND METHOD FOR PRODUCING COATED NEGATIVE ELECTRODE ACTIVE MATERIAL PARTICLES FOR LITHIUM ION BATTERIES | ＡＰＢ株式会社 | 2024-07-11 | — | — | WO | disclosed |
| EP-3808792-B1 | AQUEOUS EMULSION OF POLYETHER HAVING AT LEAST ONE REACTIVE SILYL GROUP | KANEKA BELGIUM NV (BE) | 2024-07-03 | — | — | EP | disclosed |
| CN-118201905-A | Cationic lipid | 武田药品工业株式会社 | 2024-06-14 | — | — | CN | disclosed |
| US-20240182746-A1 | POLYMER COMPOSITION COMPRISING POLYACRYLIC BLOCK COPOLYMER AND AROMATIC BASED POLYALKYLENEOXIDE AS DISPERSANT | BASF SE (DE) | 2024-06-06 | — | — | US | disclosed |
| WO-2024042211-A1 | A POLYETHER-BASED DISPERSANT WITH A LIGHT STABILIZING EFFECT | BASF SE (DE) | 2024-02-29 | — | — | WO | disclosed |
| EP-4314155-A1 | POLYMER COMPOSITION COMPRISING POLYACRYLIC BLOCK COPOLYMER AND AROMATIC BASED POLYALKYLENEOXIDE AS DISPERSANT | BASF SE (DE) | 2024-02-07 | — | — | EP | disclosed |
| US-4096254-A | STEROIDS | RICHARDSON-MERRELL INC. (US) | 1978-06-20 | — | — | US | disclosed |
| US-4088760-A | TREATMENT OF ACNE AND OILY SKIN | RICHARDSON-MERRELL INC. (US) | 1978-05-09 | — | — | US | disclosed |
| US-4078061-A | ANDROSTENONES | RICHARDSON-MERRELL INC. (US) | 1978-03-07 | — | — | US | disclosed |
| US-4078060-A | ANDROSTENONES | RICHARDSON-MERRELL INC. (US) | 1978-03-07 | — | — | US | disclosed |
| US-4055641-A | STEROID, 3-OXO-ANDROST-4-ENES | RICHARDSON-MERRELL INC. (US) | 1977-10-25 | — | — | US | disclosed |
| US-4054651-A | Method of contraception | RICHARDSON-MERRELL INC. (US) | 1977-10-18 | — | — | US | disclosed |
| US-4013762-A | STEROIDS WITHOUT ANDROGENIZING EFFECT | RICHARDSON-MERRELL INC. (US) | 1977-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096948-A1 | Lipopeptide stereoisomers, methods for preparing same, and useful intermediates | LSS, NGLY1, RPN1 | LMNA 589/4885ACE2 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.